A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Clinical trial NCT06247995 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06247995
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-14
- Primary completion
- 2031-09-09
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.